Liquidia (NASDAQ:LQDA) Insider Sells 9,218 Shares of Company Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 9,218 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $262,528.64. Following the completion of the transaction, the insider owned 126,368 shares of the company’s stock, valued at approximately $3,598,960.64. This trade represents a 6.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rajeev Saggar also recently made the following trade(s):

• On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The stock was sold at an average price of $76.84, for a total value of $2,269,392.56.
• On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The shares were sold at an average price of $74.06, for a total value of $3,703,000.00.

Liquidia Stock Down 3.1%

Shares of NASDAQ LQDA traded down $0.86 during mid-day trading on Tuesday, hitting $26.81. The company had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. The company has a market capitalization of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61. The business’s 50-day simple moving average is $63.40 and its 200 day simple moving average is $61.76. Liquidia Corporation has a 1-year low of $21.94 and a 1-year high of $93.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period in the previous year, the firm earned ($0.49) earnings per share. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. On average, analysts predict that Liquidia Corporation will post 2.05 earnings per share for the current year.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LQDA. Citigroup reiterated a “neutral” rating on shares of Liquidia in a research note on Thursday, October 1st. Needham & Company LLC cut their target price on shares of Liquidia from $110.00 to $72.00 and set a “buy” rating on the stock in a research note on Thursday, October 1st. Stephens set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. BTIG Research cut shares of Liquidia from a “buy” rating to a “neutral” rating in a research report on Thursday, October 1st. Finally, Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $83.69.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Globeflex Capital L P acquired a new stake in shares of Liquidia during the 2nd quarter worth about $175,000. Nykredit A S purchased a new stake in Liquidia during the second quarter worth approximately $177,000. Fluent Financial LLC purchased a new stake in Liquidia during the second quarter worth approximately $287,000. WINTON GROUP Ltd acquired a new position in Liquidia in the second quarter valued at approximately $335,000. Finally, Fulcrum Equity Management acquired a new position in Liquidia in the second quarter valued at approximately $399,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).